MBRX (Moleculin Biotech, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by MBRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Jonathan P. Foster | Chief Financial Officer | Buy | — | — |
| 2026-08-05 | WALTER V KLEMP | CEO and President | Buy | — | — |
| 2026-08-05 | DONALD H PICKER | Chief Science Officer | Buy | — | — |
| 2026-06-24 | Jonathan P. Foster | Chief Financial Officer | MIXED | — | — |
| 2026-06-24 | WALTER V KLEMP | CEO and President | MIXED | — | — |
| 2026-06-24 | DONALD H PICKER | Chief Science Officer | MIXED | — | — |
| 2025-11-14 | MICHAEL D CANNON | Director | A | — | — |
| 2025-11-14 | Elizabeth Cermak | Director | A | — | — |
| 2025-11-14 | Jonathan P. Foster | EVP & CFO | A | — | — |
| 2025-11-14 | John M Climaco | Director | A | — | — |
| 2025-11-14 | Joy Yan | Director | A | — | — |
| 2025-11-14 | Robert E. George | Director | A | — | — |
| 2025-11-14 | WALTER V KLEMP | CEO and President | A | — | — |
| 2025-11-14 | DONALD H PICKER | CSO | A | — | — |
| 2025-11-06 | Jonathan P. Foster | Chief Financial Officer | M | — | — |
| 2025-11-06 | DONALD H PICKER | Chief Science Officer | MIXED | — | — |
| 2025-11-06 | WALTER V KLEMP | CEO and President | MIXED | — | — |
| 2025-06-23 | WALTER V KLEMP | CEO and President | MIXED | — | — |
| 2025-06-23 | DONALD H PICKER | Chief Science Officer | MIXED | — | — |
| 2025-06-23 | Jonathan P. Foster | Chief Financial Officer | MIXED | — | — |
| 2025-06-18 | Jonathan P. Foster | Chief Financial Officer | MIXED | — | — |
| 2025-06-18 | WALTER V KLEMP | CEO and President | MIXED | — | — |
| 2024-11-06 | MICHAEL D CANNON | Director | A | — | — |
| 2024-11-06 | John M Climaco | Director | A | — | — |
| 2024-11-06 | Joy Yan | Director | A | — | — |
| 2024-11-06 | Jonathan P. Foster | Chief Financial Officer | A | — | — |
| 2024-11-06 | Elizabeth Cermak | Director | A | — | — |
| 2024-11-06 | Robert E. George | Director | A | — | — |
| 2024-11-06 | WALTER V KLEMP | CEO and President | A | — | — |
| 2024-11-06 | DONALD H PICKER | Chief Science Officer | A | — | — |
| 2024-07-05 | WALTER V KLEMP | CEO and President | MIXED | — | — |
| 2024-06-25 | DONALD H PICKER | Chief Science Officer | MIXED | — | — |
| 2024-06-25 | Jonathan P. Foster | Chief Financial Officer | MIXED | — | — |
| 2024-06-25 | WALTER V KLEMP | CEO and President | MIXED | — | — |
| 2024-06-21 | Jonathan P. Foster | Chief Financial Officer | MIXED | — | — |
| 2024-06-21 | WALTER V KLEMP | CEO and President | MIXED | — | — |
| 2024-06-21 | DONALD H PICKER | Chief Science Officer | MIXED | — | — |
| 2024-06-18 | Jonathan P. Foster | Chief Financial Officer | MIXED | — | — |
| 2024-06-18 | WALTER V KLEMP | CEO and President | MIXED | — | — |
| 2023-12-27 | Robert E. George | Director | Buy | — | — |
| 2023-12-27 | WALTER V KLEMP | CEO and President | Buy | — | — |
| 2023-12-27 | Jonathan P. Foster | Chief Financial Officer | Buy | — | — |
| 2023-07-13 | WALTER V KLEMP | CEO and President | MIXED | — | — |
| 2023-07-05 | WALTER V KLEMP | CEO and President | MIXED | — | — |
| 2023-06-26 | DONALD H PICKER | Chief Science Officer | A | — | — |
| 2023-06-26 | WALTER V KLEMP | CEO and President | A | — | — |
| 2023-06-26 | Jonathan P. Foster | Chief Financial Officer | A | — | — |
| 2023-06-22 | Jonathan P. Foster | Chief Financial Officer | MIXED | — | — |
| 2023-06-22 | WALTER V KLEMP | CEO and President | MIXED | — | — |
| 2023-06-22 | DONALD H PICKER | Chief Science Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO and President | 564,340 | — |
| — | Chief Financial Officer | 305,673 | — |
| — | Chief Science Officer | 174,086 | — |
| — | 10%+ Owner | 1,236 | — |
| — | Director | 39 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MBRX quote page; the site-wide leaderboard is on the insider transactions hub.